NCT02075463 - Study to Evaluate the Safety and Efficacy of GSK1278863 in Recombinant Human Erythropoietin (rhEPO) Hyporesponsive Hemodialysis-dependent Chronic Kidney Disease Subjects With Anemia | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 1, 2014

Primary Completion Date

March 1, 2016

Study Completion Date

March 16, 2016

Conditions

Anemia

Interventions

DRUG

GSK1278863

Film coated tablets containing 1 mg, 2 mg, 5 mg or 25 mg of GSK1278863

DRUG

Placebo

Matching placebo tablet for GSK1278863

Trial Locations (19)

14226

GSK Investigational Site, Amherst

18017

GSK Investigational Site, Bethlehem

28801

GSK Investigational Site, Asheville

31217

GSK Investigational Site, Macon

33024

GSK Investigational Site, Hollywood

33609

GSK Investigational Site, Tampa

37923

GSK Investigational Site, Knoxville

48195

GSK Investigational Site, Southgate

63074

GSK Investigational Site, Saint Ann

63110

GSK Investigational Site, St Louis

77004

GSK Investigational Site, Houston

90022

GSK Investigational Site, Los Angeles

90025

GSK Investigational Site, Los Angeles

90723

GSK Investigational Site, Paramount

91204

GSK Investigational Site, Glendale

91702

GSK Investigational Site, Azusa

92115

GSK Investigational Site, San Diego

93065

GSK Investigational Site, Simi Valley

06762

GSK Investigational Site, Middlebury